Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)
Maria Carmela Piccirillo, Quincy S. Chu, Penelope A. Bradbury, Wei Tu, Courtney H. Coschi, Federica Grosso, Marie Florescu, Manlio Mencoboni, John R. Goffin, Maria Pagano, Fortunato Ciardiello, Fabiana Letizia Cecere, Mark Vincent, Roberto Ferrara, David E. Dawe, Desirée Hao, Christopher W. Lee, Alessandro Morabito, Cesare Gridelli, Luigi Cavanna, Mussawar Iqbal, Normand Blais, Natasha B. Leighl, Paul Wheatley‐Price, Ming‐Sound Tsao, Francesca Ugo, Hazem El‐Osta, Piera Gargiulo, Pierre-Olivier Gaudreau, Dongsheng Tu, Joana Sederias, Pamela Brown-Walker, Francesco Perrone, Lesley Seymour, Scott A. Laurie
Topics & Concepts
MedicinePembrolizumabMesotheliomaPemetrexedConfidence intervalInternal medicineLung cancerInterim analysisInterimOncologyClinical trialCancerChemotherapyImmunotherapyPathologyHistoryArchaeologyCisplatinOccupational and environmental lung diseasesPleural and Pulmonary DiseasesCancer Immunotherapy and Biomarkers